{"organizations": [], "uuid": "41fdb554bb8f2049d93faa43fa5ef8537cc0b913", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-sanuwave-receives-fda-de-novo-deci/brief-sanuwave-receives-fda-de-novo-decision-to-immediately-market-dermapace-system-for-treatment-of-diabetic-foot-ulcers-in-u-s-idUSFWN1OX07U", "country": "US", "domain_rank": 408, "title": "BRIEF-Sanuwave Receives FDA De Novo Decision To Immediately Market Dermapace System For Treatment Of Diabetic Foot Ulcers In U.S.", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-02T15:12:00.000+02:00", "replies_count": 0, "uuid": "41fdb554bb8f2049d93faa43fa5ef8537cc0b913"}, "author": "", "url": "https://www.reuters.com/article/brief-sanuwave-receives-fda-de-novo-deci/brief-sanuwave-receives-fda-de-novo-decision-to-immediately-market-dermapace-system-for-treatment-of-diabetic-foot-ulcers-in-u-s-idUSFWN1OX07U", "ord_in_thread": 0, "title": "BRIEF-Sanuwave Receives FDA De Novo Decision To Immediately Market Dermapace System For Treatment Of Diabetic Foot Ulcers In U.S.", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "fda de novo", "sentiment": "negative"}, {"name": "treatment of diabetic foot ulcers in u.s. reuters", "sentiment": "none"}, {"name": "fda", "sentiment": "none"}, {"name": "reuters) - sanuwave health inc", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "novo", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "#Market News  14 PM / Updated 8 minutes ago BRIEF-Sanuwave Receives FDA De Novo Decision To Immediately Market Dermapace System For Treatment Of Diabetic Foot Ulcers In U.S. Reuters Staff 1 Min Read \nJan 2 (Reuters) - Sanuwave Health Inc: \n* SANUWAVE RECEIVES FDA DE NOVO DECISION TO IMMEDIATELY MARKET THE DERMAPACE SYSTEM FOR THE TREATMENT OF DIABETIC FOOT ULCERS IN THE U.S. Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-02T15:12:00.000+02:00", "crawled": "2018-01-02T15:28:25.006+02:00", "highlightTitle": ""}